dr. backes on rationale for lenvatinib and weekly paclitaxel in endometrial cancer
Published 4 years ago • 121 plays • Length 1:14Download video MP4
Download video MP3
Similar videos
-
0:53
dr. backes on next steps for lenvatinib and weekly paclitaxel in endometrial cancer
-
0:55
dr. backes on safety profile of lenvatinib and weekly paclitaxel in endometrial cancer
-
1:01
dr. backes on the film trial in endometrial cancer
-
0:52
investigating toxicities with lenvatinib plus paclitaxel in ovarian and endometrial cancers
-
1:08
evaluating the benefits of lenvatinib and paclitaxel in recurrent gynecologic cancers
-
1:37
dr. backes on financial toxicity considerations in ovarian cancer
-
7:26
standard frontline therapy for endometrial cancer
-
0:56
dr. backes on quality of life with parp inhibitors in ovarian cancer
-
1:39
dr. makker on synergy between lenvatinib and pembrolizumab in endometrial cancer
-
1:32
dr. makker on safety signals with lenvatinib and pembrolizumab in endometrial cancer
-
1:18
dr. backes on treatment selection with parp inhibitors in ovarian cancer
-
0:49
research priorities for metastatic endometrial cancer
-
1:02
dr. wenham on rationale for novel immunotherapy combos in ovarian cancer
-
0:59
combining lenvatinib & pembrolizumab for non-clear cell rcc: keynote-b61 study rationale
-
7:15
rebastinib plus paclitaxel shows encouraging anti-tumor activity in endometrial cancer
-
0:59
dr. taylor on the current treatment landscape for endometrial cancer
-
0:59
dr. schlumbrecht on remaining challenges in uterine leiomyosarcoma
-
1:22
dr. oaknin discusses findings of the garnet study in endometrial cancer
-
1:45
dr. ascierto on triplet of encorafenib, binimetinib, and ribociclib in melanoma